Osimertinib, a third-generation EGFR-TKI, is now the standard first-line treatment for EGFR-mutant non-small cell lung cancer and is increasingly given in the adjuvant setting for up to 3 years and in combination with chemotherapy. As exposure has lengthened and shifted toward curative-intent settings, its cardiac effe...
S. Gopu, A. Khader, S. Agrawal et al.· Cardiology in Review· 0 citations
Cardiac myosin-binding protein C (cMyBPC) is an important sarcomeric regulatory protein that plays a key role in myocardial contraction and relaxation. Through its interactions with thick and thin filament proteins, cMyBPC helps regulate cross-bridge cycling and contributes significantly to overall cardiac performance....
Chinonso Asuzu, J. Catanzaro, Tzvi Fishkin et al.· Cardiology in Review· 0 citations
Diabetes, which impacts over 500 million individuals globally, has been identified as a significant risk factor for accelerated cognitive aging, mild cognitive impairment, and various forms of dementia, including Alzheimer's disease and vascular dementia. Despite its clinical relevance, cognitive decline remains an und...
Alok Kumar Singh, Vennela Dunde, Maitri H Maurya et al.· Cardiology in Review· 0 citations
Dyslipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease, and many high-risk patients do not reach target low-density lipoprotein cholesterol (LDL-C) levels despite conventional therapy. Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9...
Ahmed Talkhan, M. Elkasaby, Ahmed S. A. Osman et al.· Cardiology in Review· 0 citations
Selective aldosterone synthase inhibitors (ASIs), including baxdrostat and lorundrostat, target CYP11B2 while sparing cortisol synthesis, offering a novel strategy for resistant and uncontrolled hypertension. Yet existing meta-analyses have included nonselective agents or omitted the latest phase 3 data. We searched Pu...
Noha Hammad, M. Elkasaby, A. Gadelmawla et al.· Cardiology in Review· 0 citations
Baxdrostat lowers blood pressure and aldosterone levels in uncontrolled and resistant hypertension but increases potassium and modestly reduces eGFR, supporting careful laboratory monitoring and longer trials to evaluate long-term clinical outcomes.
A. Gadelmawla, A. W. Hageen, R. Rateb et al.· Cardiology in Review· 0 citations
Patent ductus arteriosus (PDA) is a common congenital heart defect. PDA disproportionately affects low-birth-weight infants, resulting in an incidence of 21% among preterm births as compared to 0.05% in the general population. The ductus arteriosus remains patent in the fetus, allowing maternal blood to directly enter...
Rithvik Swamynathan, L. Dolan, W. Frishman et al.· Cardiology in Review· 0 citations
Integration of echocardiography, computed tomography, CMR, and emerging positron emission tomography and artificial intelligence-based approaches can help address diagnostic uncertainty in aortic stenosis.
H. Itani, M. Moumneh, Ahmed A. Zayed et al.· Cardiology in Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
